James Nicholson (ECR), in writing. - I voted in favour of clinical trials reform due to my concerns with the current lack of transparency in the clinical trials process, which the proposals sought to address. Many details of clinical trials process are not published, while information about unsuccessful trials is rarer still. These proposals will ensure that pharmaceutical companies and academic researchers will have to post the results of all their trials in a publicly-accessible database. This is simply good practice in the medical industry and will certainly increase trust amongst patients. I support streamlining the rules on clinical trials across Europe in order to improve the alarming decline of trials conducted in the EU between 2007 and 2011 (25[nbsp ]% decrease). I am also in favour of facilitating increasing numbers of cross-border clinical trials and ensuring a minimum standard of patient safety. Cross-border trials harness the potential to boost efforts in the fight against rare diseases – in Northern Ireland more than one in five patients diagnosed with cancer have participated in clinical trials (6[nbsp ]400 between April 2008 and September 2013). Through collaborative efforts in other regions and Member States, we will hopefully begin to see the development of new disease prevention, diagnosis and treatment.